Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cystetine Triphosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 known ✓ | P41231 | 5/20 | 0.67 |
| ▸ | P2RY4 known ✓ | P51582 | 3/20 | 0.61 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.57 |
| ▸ | P2RY6 known ✓ | Q15077 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | GLA | P06280 | 1/20 | 0.75 |
| ▸ | ST6GAL1 | P15907 | 10/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.57 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.57 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11616961 | 0.95 | TSHR (0.78) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Cystetine Triphosphate SCHEMBL27611738 | 0.94 | TSHR (0.73) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Cystetine Triphosphate SCHEMBL11613107 | 0.94 | TSHR (0.79) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| SCHEMBL5407898 | 0.91 | TSHR (0.81) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| SCHEMBL29356399 | 0.91 | TSHR (0.81) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Potassium Ion SCHEMBL10585798 | 0.91 | TSHR (0.80) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Cystetine Triphosphate SCHEMBL2194120 | 0.90 | TSHR (0.79) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Cystetine Triphosphate SCHEMBL9101211 | 0.90 | TSHR (0.81) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Cystetine Triphosphate SCHEMBL31405617 | 0.89 | TSHR (0.80) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Cystetine Triphosphate SCHEMBL10826769 | 0.89 | TSHR (0.80) | TSHRGLAP2RY2ST6GAL1P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195689-A1 | GLYCOMIMETIC LIGANDS | AVICEDA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4457235-A1 | GLYCOMIMETIC LIGANDS | Aviceda Therapeutics, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| US-20240189335-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | EMORY UNIVERSITY | 2024-06-13 | — | — | US | disclosed |
| US-11903959-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | EMORY UNIVERSITY (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230293566-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | EMORY UNIVERSITY | 2023-09-21 | — | — | US | disclosed |
| WO-2023129737-A1 | GLYCOMIMETIC LIGANDS | AVICEDA THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| CN-116334020-A | 6' -sialyltransferase mutant and application thereof | 南京工业大学 | 2023-06-27 | — | — | CN | disclosed |
| US-11628181-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | EMORY UNIVERSITY (US) | 2023-04-18 | — | — | US | disclosed |
| EP-4017501-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | Emory University (US) | 2022-06-29 | — | — | EP | disclosed |
| US-11331331-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | EMORY UNIVERSITY (US) | 2022-05-17 | — | — | US | disclosed |
| WO-2016106050-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | EMORY UNIVERSITY (US) | 2016-06-30 | — | — | WO | disclosed |
| CN-101658498-B | Freeze-drying manufactured product of cytidine triphosphate disodium and arginine and preparation method thereof | GUANGDONG P D | 2012-01-04 | — | — | CN | disclosed |
| CN-101658498-B | Freeze-drying manufactured product of cytidine triphosphate disodium and arginine and preparation method thereof | GUANGDONG P D | 2012-01-04 | — | — | CN | disclosed |
| US-20110171737-A1 | PROTEIN ENGINEERING | DUKE UNIVERSITY | 2011-07-14 | — | — | US | disclosed |
| CN-101658498-A | Freeze-drying manufactured product of cytidine triphosphate disodium and arginine and preparation method thereof | GUANGDONG P D | 2010-03-03 | — | — | CN | disclosed |
| CN-101658498-A | Freeze-drying manufactured product of cytidine triphosphate disodium and arginine and preparation method thereof | GUANGDONG P D | 2010-03-03 | — | — | CN | disclosed |
| EP-1911850-A1 | Method of producing 6-thio-sialylated glycoproteins and glycoconjugates | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2008-04-16 | — | — | EP | disclosed |
| CN-1660126-A | Medication of combination of sodium cytidine triphosphate and ebselen | YANG XIHONG (CN) | 2005-08-31 | — | — | CN | disclosed |
| CN-1562345-A | Drug combination including activator for metabolism of brain and free radical scavenger | YANG XIHONG (CN) | 2005-01-12 | — | — | CN | disclosed |
| CN-1513468-A | Compound medicine of sodium citicoline and disodium cytidine triphosphate | 杨喜鸿 | 2004-07-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171737-A1 | PROTEIN ENGINEERING | MRPL21, RNGTT, SERBP1 | P2RY2 4830/4885P2RY4 4863/4885THRB 2357/4885 |
| US-11331331-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | ENTPD1, NME2, NME1 | P2RY2 843/4885P2RY4 232/4885THRB 4460/4885 |
| US-20250195689-A1 | GLYCOMIMETIC LIGANDS | SIGLEC9, SIGLEC7, LGALS2 | P2RY2 1493/4885P2RY4 1338/4885THRB 3137/4885 |
| US-11628181-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | TYMP, ENTPD5, ADA | P2RY2 1364/4885P2RY4 592/4885THRB 4778/4885 |
| US-11903959-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | ENTPD1, NME2, NME1 | P2RY2 843/4885P2RY4 232/4885THRB 4460/4885 |
| US-20240189335-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | ENTPD1, NME2, NME1 | P2RY2 843/4885P2RY4 232/4885THRB 4460/4885 |
| US-20230293566-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | TYMP, ADA, CDA | P2RY2 1313/4885P2RY4 561/4885THRB 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.